|
Relapse-free and overall survival with respect to biomarker score for test and validation sets |
|||||||
| Survival |
Division |
Test set |
Validation set |
||||
| n |
Median RFS, years (95% CI) |
10-year RFS, percentage (SEM) |
n |
Median RFS, years (95% CI) |
10 year RFS, percentage (SEM) |
||
|
|
|||||||
| RFS |
Overall cohort |
313 |
5.2 (3.9–6.5) |
38.3 (2.9) |
289 |
5.8 (4.4–7.3) |
38.1 (2.9) |
| 0 |
38/227 |
NR |
75.4 (7.1) |
40/219 |
9.7 (5.5–14.0) |
47.8 (8.4) |
|
| 1–4 |
154/227 |
4.8 (3.6–6.1) |
35.3 (4.1) |
146/219 |
5.8 (3.9–7.7) |
37.8 (4.2) |
|
| 5–8 |
35/227 |
1.6 (0.8–2.3) |
19.3 (7.0) |
33/219 |
2.4 (0.9–3.8) |
30.3 (8.0) |
|
| All markers |
227/227 |
5.2 (3.6–6.9) |
39.8 (3.4) |
219/219 |
5.8 (4.2–7.5) |
38.5 (3.4) |
|
| OS |
Overall cohort |
313 |
6.7 (5.7–7.8) |
39.5 (3.4) |
289 |
7.3 (5.9–8.6) |
39.1 (2.9) |
| 0 |
38/227 |
15.5 (10.9–20.1) |
67.6 (7.7) |
40/219 |
9.3 (5.5–13.1) |
47.5 (7.9) |
|
| 1–4 |
154/227 |
6.4 (5.3–7.5) |
35.1 (3.8) |
146/219 |
7.8 (5.8–9.9) |
38.4 (4.0) |
|
| 5–8 |
35/227 |
2.7 (1.1–4.3) |
21.6 (6.8) |
33/219 |
3.3 (1.7–4.9) |
30.3 (8.0) |
|
| All markers |
227/227 |
6.6 (5.2–8.0) |
38.2 (3.2) |
219/219 |
7.6 (6.0–9.1) |
38.8 (3.3) |
|
|
Relapse-free and overall survival are presented in the test and validation sets for the overall cohorts, for the subsets with expression scores available for all eight biomarkers assessed and with respect to patient subgroups for biomarker scores of 0, 1 to 4, and 5 to 8. RFS, relapse-free survival; OS, overall survival; NR, not reached; CI, confidence interval. | |||||||
Crabb et al. Breast Cancer Research 2008 10:R6 doi:10.1186/bcr1847 |
|||||||